Please the a plus sign (+) inside this box +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid QMB control number.

## Substitute for form 1449A/PTO Complete if Known **Application Number** 10/067,996 INFORMATION DISCLOSURE Filing Date February 8, 2002 STATEMENT BY APPLICANT First Named Inventor Allen T. Hopper Group Art Unit 1624 (use as many sheets as necessary) **Examiner Name** Mark L. Berch Sheet of 2 Attorney Docket Number MEMORY-2


			U.S. PATENT DOCUM	MENTS		
Examiner Initials *	Cite No.1	U.S. Patent Document  Number Kind Code²  (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Figures Appear	
MB 2004		2004/0102460	Hopper et al.	5/27/2004		
MB		5,073,559	Coates	12/17/1991		
М		5,525,606 ·	Moschel et al.	6/11/1996		
			-			
		† -   -		<del> </del>		

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document			Name of Patentee	Date of Publication of	Pages, Columns, Lines, Where Relevant	
		Office <sup>3</sup>		ind Code⁵ if known)	or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	Te
MB		JP	62-240622	2		10/21/87		
MB		JP	05-001066	5		1/8/93		
		JP	20000-7277	'3		3/7/2000		
		<del> </del>						
		<del>                                     </del>				·		
				,				
	<del></del>	<del> </del> -			<u> </u>			
		<del> </del>					<del></del>	
		ļ						
		1						

Examiner Signature /Mark L. Berch/	Date Considered	12/20/2006
------------------------------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-latter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark hee if English language Translation is attached.



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete If Known		
INICO	D 84 A T14	ON DIE	CLOCUDE	Application Number	10/067,996	
			CLOSURE	Filing Date	February 8, 2002	
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Allen T. Hopper	
		e.		Group Art Unit	1624	
(use as many sheets as necessary)			necessary)	Examiner Name	Mark L. Berch	
Sheet	2	of	2	Attorney Docket Number	MEMORY-2	

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	τ²
MB		Japanese Patent Abstract No. 05-001066 dated January 8, 1993	
МВ		Japanese Patent Abstract No. 62-240622 dated October 21, 1987	
МВ		Japanese Patent Abstract No. 20000-072773, with partial translation	
MB		RABOISSON et al., "Design, synthesis and structure – activity relationships of series of 9-substituted adenine derivatives" Eur. J. Med. Chem., 38, 2003, pgs. 199-214	
MB		REIMUND et al., "Anti-TNF-α Properties of New 9-Benzyladenine Derivatives with Selective", Biochemical & BioPhysical, (2001), pgs. 427-434	
		·	
		•	
			<del> </del>
		·	

Evaminar	/Mark L. Berch/	D-4-	12/20/2006
Examiner	/ mark L. berch/	Date	12/20/2000
Signature		Canaidanad	
( Signature		Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case, Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

÷

<sup>1</sup> Unique citation designation number, 2 Applicant is to place a check mark here if English language Translation is attached.